Huntington's Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics
The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates and increased awareness globally. Advancements in gene-targeting and disease-modifying therapies, along with a robust clinical pipeline, are addressing critical unmet needs. Active government support and educational initiatives are further enhancing diagnosis and treatment uptake. Together, these factors create a strong foundation for market expansion in the coming years.
New York, USA, June 03, 2025 (GLOBE NEWSWIRE) -- Huntington's Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight
The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates and increased awareness globally. Advancements in gene-targeting and disease-modifying therapies, along with a robust clinical pipeline, are addressing critical unmet needs. Active government support and educational initiatives are further enhancing diagnosis and treatment uptake. Together, these factors create a strong foundation for market expansion in the coming years.
DelveInsight's 'Huntington's Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Huntington's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Huntington's disease pipeline domain.
Key Takeaways from the Huntington's Disease Pipeline Report
DelveInsight's Huntington's disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline Huntington's disease drugs.
Key Huntington's disease companies such as Hoffmann-La Roche, Medibiofarma, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, Skyhawk Therapeutics, BPG Bio, and others are evaluating new Huntington's disease drugs to improve the treatment landscape.
Promising pipeline Huntington's disease therapies, such as RG6042, MBF 015, PTC518, ANX-005, ALN-HTT02, NP001, SKY 0515, Research Programme: HDD, and others are in different phases of Huntington's disease clinical trials.
In April 2025, the FDA granted a breakthrough therapy designation to AMT-130 (uniQuire) for the treatment of Huntington's disease. Previously, AMT-130 was also granted a regenerative medicine advanced therapy designation and orphan drug designation for this indication.
In April 2025, Prilenia Therapeutics announced that it had entered into a collaboration and license agreement with Ferrer for the development and commercialization of pridopidine in Europe and other select markets.
In March 2025, Skyhawk Therapeutics presented their novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization (HDYO), at the biannual HYDO International Congress in Prague, Czech Republic.
In December 2024, Novartis announced that it had entered into a global licensing and collaboration agreement with PTC Therapeutics for PTC518, an HTT mRNA splice modulator for the treatment of Huntington's disease. Under the terms of the agreement, Novartis will pay USD 1 billion upfront and up to USD 1.9 billion in development, regulatory, and sales milestones. Novartis will also share profits in the US and pay tiered royalties on sales outside the US.
In September 2024, PTC Therapeutics announced that the FDA had granted Fast Track designation to the PTC518 program for the treatment of Huntington's disease.
In September 2024, the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) for Prilenia Therapeutics' pridopidine for the treatment of adults with Huntington's disease.
Request a sample and discover the recent advances in Huntington's disease drugs @ Huntington's Disease Pipeline Report
The Huntington's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Huntington's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Huntington's disease clinical trial landscape.
Huntington's Disease Overview
Huntington's disease is a hereditary, progressive neurodegenerative condition marked by the gradual onset of involuntary muscle movements—affecting the hands, feet, face, and trunk—and a steady decline in cognitive abilities and memory. It impacts the central region of the brain, leading to difficulties in movement, emotional regulation, and cognitive functions. Symptoms often appear between ages 30 and 50 but can emerge as early as age 2 or as late as 80. A hallmark feature of the disease is the presence of rapid, uncontrolled movements such as muscle jerks or tics. As the condition advances, patients may experience loss of coordination, speech difficulties, memory deterioration, and worsening choreiform movements, along with personality and behavioral changes.
Huntington's disease follows an autosomal dominant inheritance pattern, meaning only one copy of the faulty gene is needed to cause the disease. It is triggered by a mutation in a single gene on chromosome 4, which encodes the huntingtin protein. While the exact role of huntingtin remains unclear, its mutated form disrupts normal brain function, leading to involuntary movements, severe cognitive decline, and emotional disturbances such as depression and irritability. The mutation involves an expansion of a CAG repeat segment within the gene. Typically, this segment repeats 17 to 20 times in a healthy gene, but in Huntington's disease, the number of repeats rises to 40 or more.
Diagnosing Huntington's disease involves a comprehensive clinical assessment, patient history, and several specialized tests. These may include blood work, genetic testing to detect mutations in the HTT gene, and brain imaging techniques such as CT scans, MRI, and EEG. CT and MRI provide detailed cross-sectional images of the brain, while EEG measures the brain's electrical activity to support diagnosis.
Currently, there is no cure for Huntington's disease, and treatment is aimed at alleviating symptoms. The only two FDA-approved medications—Austedo and Xenazine—are indicated specifically for managing chorea related to Huntington's. Additional symptom management may include antidepressants, antipsychotics, and mood stabilizers to address psychiatric symptoms. Supportive therapies and multidisciplinary care are also critical in improving the quality of life for individuals affected by this condition.Find out more about Huntington's disease drugs @ Huntington's Disease Treatment
A snapshot of the Pipeline Huntington's Disease Drugs mentioned in the report:
Drugs
Company
Phase
MoA
RoA
MBF 015
Medibiofarma
II
HDAC1/C2 inhibitors
Oral
PTC518
PTC Therapeutics
II
HD protein inhibitors; RNA splicing modulators
Oral
ANX-005
Annexon
II
Complement C1 inhibitors
Intravenous
ALN-HTT02
Alnylam Pharmaceuticals
I
RNA interference
Intrathecal
NP001
Neuvivo
I
Macrophage modulators
Unspecified
SKY 0515
Skyhawk Therapeutics
I
RNA splicing modulators
Oral
Learn more about the emerging Huntington's disease therapies @ Huntington's Disease Clinical Trials
Huntington's Disease Therapeutics Assessment
The Huntington's disease pipeline report proffers an integral view of the emerging Huntington's disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Huntington's Disease Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment By Mechanism of Action: HDAC1/C2 inhibitors, RNA interference, HD protein inhibitors, RNA splicing modulators, Macrophage modulators, Complement C1 inhibitors
Key Huntington's Disease Companies: Hoffmann-La Roche, Medibiofarma, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, Skyhawk Therapeutics, BPG Bio, and others.
Key Huntington's Disease Pipeline Therapies: RG6042, MBF 015, PTC518, ANX-005, ALN-HTT02, NP001, SKY 0515, Research Programme: HDD, and others.
Dive deep into rich insights for new Huntington's disease treatments, visit @ Huntington's Disease Drugs
Table of Contents
1.
Huntington's Disease Pipeline Report Introduction
2.
Huntington's Disease Pipeline Report Executive Summary
3.
Huntington's Disease Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Huntington's Disease Clinical Trial Therapeutics
6.
Huntington's Disease Pipeline: Late-Stage Products (Pre-registration)
7.
Huntington's Disease Pipeline: Late-Stage Products (Phase III)
8.
Huntington's Disease Pipeline: Mid-Stage Products (Phase II)
9.
Huntington's Disease Pipeline: Early-Stage Products (Phase I)
10.
Huntington's Disease Pipeline Therapeutics Assessment
11.
Inactive Products in the Huntington's Disease Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products in the Huntington's Disease Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the Huntington's disease pipeline therapeutics, reach out @ Huntington's Disease Therapeutics
Related Reports
Huntington's Disease Epidemiology Forecast
Huntington's Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Huntington's disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Huntington's Disease Market
Huntington's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Huntington's disease companies, including Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharma, among others.
Wilson Disease Market
Wilson Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wilson disease companies, including Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, among others.
Wilson Disease Pipeline
Wilson Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wilson disease companies, including Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, among others.
Bipolar Disorder Pipeline
Bipolar Disorder Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar disorder companies, including Vanda Pharmaceuticals, Pear Therapeutics, Sunovion, Lyndra Therapeutics, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Falls Council Oks new flight path for Rainbow Air
Niagara Falls City Council members voted Wednesday night to approve a new flight plan for Rainbow Air, as the longtime Falls tour operator prepares to open its new facilities just off of Buffalo Avenue. Rainbow was seeking to modify its current operational flight path as it is set to begin operations at its new $15 million tourism center at 56 Acheson Drive opening on June 23. The new route was endorsed by the union representing air traffic controllers at the Falls airport as the quietest and safest flight path possible. 'We have reviewed the flight path of Rainbow Air. We endorse it,' said Daniel Leonard, the president of the local chapter of the air traffic controllers union. 'It is the safest path and the least disruptive to our new giant balloon flight (near the falls).' Leonard said new helicopters that will be operated by Rainbow Air are also the most 'eco-friendly' in operation currently. 'The flight path also provides, in case of emergency, the best survivability,' Leonard said. 'It gives (the helicopter pilots) options.' One of those pilots, Mark Chamberlain, told the council that the Federal Aviation Administration (FAA)-approved flight plan was adopted after considering safety and noise as the most important issues. 'It was designed with the help of the FAA and the considerations were safety first and then noise, which has been an issue before, Chamberlain said. He said the flights will operate at a height of 3,000 feet, 500 feet higher than the company's previous flight plan. Take-offs from the new helipad will also get out of neighborhood air space and over the Niagara River quicker than before. 'We were looking to reduce the noise footprint,' Chamberlain said. 'The Airbus H-130 is the only helicopter allowed to fly over national parks and it's the quietest in the industry.' Rainbow Air has described its new heliport and headquarters as 'the largest private tourism development in Niagara Falls in many years.' The project is located adjacent to the former Carborundum Center on Buffalo Avenue. It includes two new helipads and a 30,000-square-foot building that houses aviation-related features. Representatives of Rainbow Air said they have upgraded their fleet with brand new Airbus H-130 helicopters that seat seven passengers plus the pilot. They also noted that the interiors in the new choppers are quiet enough for an audio tour to be played on speakers in the cabin, with translations into several languages for international guests. Rainbow Air, which was established in 1995, had previously operated its tours from a landing pad near the Niagara River gorge. The tour company said that the gorge pad location required an inconvenient take-off procedure and was the source of constant noise complaints from some South End residents and businesses. The company has been operating from the Niagara Falls International Airport during the construction of its new tourism center. From its new location, helicopters will fly over Goat Island before making a loop over downtown Niagara Falls. After flying over the Rainbow Bridge, the helicopter will go along the Canadian side to get a view of the Horseshoe Falls before following that route back to the helipad. Flights will last between 12 and 14 minutes, depending on the weather conditions. The tourism center is accessed off Acheson Drive from Buffalo Avenue. It includes room for three helicopters and two helipads, an outdoor dining/gathering area and parking for both cars and buses. The single-story indoor facility contains a maintenance hangar, an aviation heritage center that will present Niagara Falls' role in the history of flight, and a retail sales area with convenience food and drink items. The facility also has an entertainment center with 15 custom-designed 3-D flight simulators that allow visitors to have the experience of flying over the Falls. The project's architect, Aaron Faegre, said the new home for Rainbow Air was chosen to allow the company's helicopters 'a quick departure to the south, over the Niagara River,' which will allow the aircraft to 'climb to altitude quickly and minimize noise.' The flight path of the helicopters in and around the Falls is tightly controlled by the U.S. Federal Aviation Administration and Air Transport Canada. Rainbow Air officials said they have conducted studies that show that the noise from departing helicopters at the new site is no greater than the noise of trucks operating on Buffalo Avenue. 'We sought to minimize noise downtown by moving here,' Faegre said. Rainbow's director of operations, Paul Faltyn, has said the project will allow Rainbow to become 'a year-round destination' in the Falls.
Business Upturn
5 hours ago
- Business Upturn
ProZenith Launches Natural Supplement Formulated for Weight Management Support
By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
5 hours ago
- Business Upturn
Grupo Aeroportuario Del Pacifico Announces Approval Of Maximum Tariffs And Capital Development Program For 2026-2030 For Montego Bay Airport In Jamaica
By GlobeNewswire Published on June 7, 2025, 08:25 IST GUADALAJARA, Mexico, June 06, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) ('the Company' or 'GAP') announces the conclusion of the ordinary review process for the maximum tariffs per passenger and committed investments included in the Capital Development Program of Montego Bay for the 2026–2030 period. The maximum passenger charges are expressed in U.S. dollars and will apply to each year as specified in the following table: Airport 2026 2027 2028 2029 2030 Montego Bay 17.38 17.79 18.22 18.65 19.07 The investments approved by the Authority and committed under the Capital Development Program are expressed in millions of U.S. dollars and must be deployed according to the following schedule: Airport 2026 2027 2028 2029 2030 Total Montego Bay 38.4 39.4 18.4 11.6 10.3 118.1 Company Description Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico's Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP's shares were listed on the New York Stock Exchange under the ticker symbol 'PAC' and on the Mexican Stock Exchange under the ticker symbol 'GAP'. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019. This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management's current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words 'anticipates', 'believes', 'estimates', 'expects', 'plans' and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations. In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the 'Ley del Mercado de Valores', GAP has implemented a 'whistleblower' program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is or by email at [email protected]. GAP's Audit Committee will be notified of all complaints for immediate investigation. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
